Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.58 +0.38 (+0.57%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
59 60 Next >
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
Via Benzinga
AstraZeneca and Merck Receives European Commission Approval For Expanded Use In Breast Cancer Therapy
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody
Via Benzinga
Recap: AstraZeneca Q2 Earnings
  AstraZeneca (NASDAQ:AZN) reported its Q2 earnings results on Friday, July 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Via Benzinga
3-D Portfolio: Discounts, Diversification, And Dividends
When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can... 
Via Talk Markets
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.  
Via Benzinga
AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments
The company cited the contribution from its Covid drugs as part of its guidance boost. 
Via Investor's Business Daily
AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout
The company is asking for approval of three drugs in Europe and the U.S. 
Via Investor's Business Daily
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
The major indexes made big moves amid key earnings and another big Fed rate hike. 
Via Investor's Business Daily
Benzinga Before The Bell: Apple's Strong China Revenue, Amazon's EV Partnership, Jack Ma To Cede Control Of Ant Financial And Other Top Financial Stories Friday, July 29
Reuters Tencent’s Overseas Ambitions Face Resistance From India 
Via Benzinga
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance
Via Benzinga
Earnings Scheduled For July 29, 2022
Companies Reporting Before The Bell • Capital Product Partners (NASDAQ:CPLP) is expected to report quarterly earnings at $1.13 per share on revenue of $72.73 million. 
Via Benzinga
$100 Invested In AstraZeneca 5 Years Ago Would Be Worth This Much Today
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 6.99% on an annualized basis producing an average annual return of 17.21%. Currently, AstraZeneca has a market... 
Via Benzinga
FDA Accepts AstraZeneca's Submission For Low Breast Cancer Candidate Under Priority Review
The United States Food and Drug Administration (FDA) has accepted to review the supplemental Biologics License Application (sBLA) of AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo’s lead asset ENHERTU... 
Via Benzinga
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
From AstraZeneca
Via Business Wire
U.S. Stock Futures Higher; Crude Oil Rises 1%
Pre-open movers 
Via Benzinga
Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments
Via Benzinga
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
This Is What Whales Are Betting On AstraZeneca
Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.